Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 209

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

Open access
Damaj, Gandhi, Duhamel, Alain, Robin, Marie, Beguin, Yves, Michallet, Mauricette, Mohty, Mohamad, Vigouroux, Stephane, Bories, Pierre, Garnier, Alice, El Cheikh, Jean, Bulabois, Claude-Eric, Huynh, Anne, Bay, Jacques-Olivier, Legrand, Faeyzeh, Deconinck, Eric, Fegueux, Nathalie, Clement, Laurence, Dauriac, Charles, Maillard, Natacha, Cornillon, Jérôme, Ades, Lionel, Guillerm, Gaelle, Schmidt-Tanguy, Aline, Marjanovic, Zora, Park, Sophie, Rubio, Marie-Thérèse, Marolleau, Jean-Pierre, Garnier, Federico, Fenaux, ierre, Yakoub-Agha, Ibrahim · 2012 · Journal of Clinical Oncology

Abstract

Purpose: To investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell transplantation (alloSCT) for myelodysplastic syndrome (MDS). Patients and Methods: Of the 265 consecutive patients who underwent alloSCT for MDS between October 2005 and December 2009, 163 had received cytoreductive treatment prior to transplantation, including induction chemotherapy (ICT) alone (ICT group; n = 98), AZA alone (AZA group; n = 48), or AZA preceded or followed by ICT (AZA-ICT group; n = 17). At diagnosis, 126 patients (77%) had an excess of marrow blasts, and 95 patients (58%) had intermediate-2 or high-risk MDS according to the International Prognostic Scoring System (IPSS). Progression to more advanced disease before alloSCT was recorded in 67 patients. Donors were sibling (n = 75) or HLA-matched unrelated (10/10; n = 88). They received blood (n = 142) or marrow (n = 21) grafts following either myeloablative (n = 33) or reduced intensity (n = 130) conditioning. Results: With a median follow-up of 38.7 months, 3-year outcomes in the AZA, ICT, and AZA-ICT groups were 55%, 48%, and 32% (P = .07) for overall survival (OS); 42%, 44%, and 29% (P = .14) for event-free survival (EFS); 40%, 37%, and 36% (P = .86) for relapse; and 19%, 20%, and 35% (P = .24) for nonrelapse mortality (NRM), respectively. Multivariate analysis confirmed the absence of statistical differences between the AZA and the ICT groups in terms of OS, EFS, relapse, and NRM. Conclusion: With the goal of downstaging underlying disease before alloSCT, AZA alone led to outcomes similar to those for standard ICT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.44.3499

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 209

Metadata

Authors
Damaj, G., Duhamel, A., Robin, M., Beguin, Y., Michallet, M., Mohty, M., Vigouroux, S., Bories, P., Garnier, A., El Cheikh, J., Bulabois, C.-E., Huynh, A., Bay, J.-O., Legrand, F., Deconinck, E., Fegueux, N., Clement, L., Dauriac, C., Maillard, N., Cornillon, J., Ades, L., Guillerm, G., Schmidt-Tanguy, A., Marjanovic, Z., Park, S., Rubio, M.-T., Marolleau, J.-P., Garnier, F., Fenaux, I., & Yakoub-Agha, I.
Venue
Journal of Clinical Oncology
Published
2012-12-20
Volume
30
Issue
36
Pages
4533-4540
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2098454439
Cited by
209
References
2
FWCI
11.52
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. https://app.cochat.ai/papers/10.1200/jco.2012.44.3499
The paper
Damaj, G., Duhamel, A., Robin, M., Beguin, Y., Michallet, M., Mohty, M., Vigouroux, S., Bories, P., Garnier, A., El Cheikh, J., Bulabois, C.-E., Huynh, A., Bay, J.-O., Legrand, F., Deconinck, E., Fegueux, N., Clement, L., Dauriac, C., Maillard, N., . . . Yakoub-Agha, I. (2012). Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.44.3499

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.